Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-16
2010-02-09
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252010, C514S256000, C514S332000, C514S333000, C514S350000, C514S352000, C546S255000, C546S256000, C546S268100, C546S304000, C544S316000, C544S318000, C544S405000, C544S406000
Reexamination Certificate
active
07659272
ABSTRACT:
The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
REFERENCES:
patent: 5217976 (1993-06-01), Ratcliffe et al.
patent: 5236937 (1993-08-01), Bradbury et al.
patent: 5294620 (1994-03-01), Ratcliffe et al.
patent: 5541186 (1996-07-01), Breu et al.
patent: 5589478 (1996-12-01), Yamada et al.
patent: 6136971 (2000-10-01), Harrington et al.
patent: 6939885 (2005-09-01), Ungashe et al.
patent: 2004/0167113 (2004-08-01), Ugashe et al.
patent: 2004/0171654 (2004-09-01), Ugashe et al.
patent: 2005/0137193 (2005-06-01), Ungashe et al.
patent: WO 2004/046092 (2004-06-01), None
patent: WO 2004/085384 (2004-10-01), None
patent: WO 2005/112925 (2005-12-01), None
Silvestri et al. Medicinal Chemistry Research, 11(4): 195-218, 2002. CA 138:187588, 2002.
Hatse et al. FEBS Letters 527255-262, 2002.
Street et al. Journal of Chemical Research, Synopses, 5: 154-155, 1987. CA 108:37599,1988.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Kelsall et al. Immunol. Rev. 20691): 132-148, 2005.
Yu et al. J. Immunol. 164(3): 1293-1305, 2000.
International Search Report issued in PCT Application No. PCT/US03/16090, which corresponds to U.S. Appl. No. 11/391,633.
Street, Jonathan D., et al., “Cyclizing nucleophilic addition to azinium systems. Part 2. Reactions of 3-acylpyridinium hydrazones,”Journal of Chemical Research, Synopses, vol. 5 (1987) pp. 154-155 (abstract only).
Street, Jonathan D., et al., “Cyclising Nucleophilic Addition to Azinium Systems. Part 2. Reactions of 3-Acylpyridinium Hydrazones,”Journal of Chemical Research(S) (1987) pp. 154-155.
Dannhardt, Gerd, et al., “COX-1/COX-2 inhibitors based on the methanone moiety,”European Journal of Medicinal Chemistry, vol. 37 (Feb. 2002) pp. 147-161.
Supplementary European search report issued Feb. 1, 2006 in European Application No. EP 03755422.7, which corresponds to U.S. Appl. No. 10/443,155.
International Search Report issued in PCT Application No. PCT/US03/16090, which corresponds to U.S. Appl. No. 11/391,633, Oct. 20, 2003.
Fleming Paul
Harriman Geraldine C. B.
Shaowu Chen
Shi Zhan
Balasubramanian Venkataraman
Millennium Pharmaceuticals Inc.
LandOfFree
CCR9 inhibitors and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CCR9 inhibitors and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCR9 inhibitors and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4173838